Neoadjuvant Therapy to Downstage the Extent of Resection of Gastrointestinal Stromal Tumors.

ABSTRACT:

Introduction

Gastrointestinal stromal tumors (GIST) are rare malignant tumors in terms of incidence, and they are not linked to specific symptoms. Often, primary tumors, particularly of the stomach, rectum, or rectovaginal space, are quite large when detected, and multivisceral resection seems to be the treatment of choice as the mainstay of therapy is complete tumor removal. If a gain-of-function mutation in the KIT gene is present, drug therapy with receptor tyrosine kinase inhibitors (RTKIs) might significantly downstage primary GIST tumors.

Methods

A review of the literature was performed to identify the current evidence for preoperative treatment of GIST regarding toxicity, efficacy, and oncological outcome, including mutational data from our own database.

Res

SUBMITTER: Jakob J 

PROVIDER: S-EPMC6257203 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature